Disease-Specific Template - Revision history

Jennelleh at 17:47, 3 October 2023

2023-10-03T17:47:03Z

← Older revision		Revision as of 12:47, 3 October 2023
Line 232:		Line 232:

	==References==		==References==
			<references />
	(use "Cite" icon at top of page)		(use "Cite" icon at top of page)

Bailey.Glen at 18:32, 9 February 2023

2023-02-09T18:32:24Z

← Older revision		Revision as of 13:32, 9 February 2023
Line 233:		Line 233:
	==References==		==References==
	(use "Cite" icon at top of page)		(use "Cite" icon at top of page)
	~~===~~EXAMPLE Book~~===~~
			'''EXAMPLE Book'''

	#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.		#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.

Kilannin.Krysiak: Removed author instructions not designed for the wiki template

2021-10-29T16:18:29Z

Removed author instructions not designed for the wiki template

← Older revision		Revision as of 11:18, 29 October 2021
Line 1:		Line 1:
	''(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions]] and [[Frequently Asked Questions (FAQs)\|FAQs]] as well as contact your [[Leadership\|Associate Editor]] or [[Mailto:CCGA@cancergenomics.org\|Technical Support]].)''
	==Primary Author(s)*==		==Primary Author(s)*==

	Put your text here ~~(''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics)~~		Put your text here

	__TOC__		__TOC__
Line 16:		Line 15:
	==Definition / Description of Disease==		==Definition / Description of Disease==

	Put your text here (''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'')		Put your text here

	==Synonyms / Terminology==		==Synonyms / Terminology==

	Put your text here ~~(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'')~~		Put your text here

	==Epidemiology / Prevalence==		==Epidemiology / Prevalence==
Line 28:		Line 27:
	==Clinical Features==		==Clinical Features==

	Put your text here and fill in the table ~~(''Instruction: Can include references in the table'')~~		Put your text here and fill in the table
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Signs and Symptoms'''		\|'''Signs and Symptoms'''
Line 47:		Line 46:
	==Sites of Involvement==		==Sites of Involvement==

	Put your text here ~~(''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'')~~		Put your text here

	==Morphologic Features==		==Morphologic Features==
Line 55:		Line 54:
	==Immunophenotype==		==Immunophenotype==

	Put your text here and fill in the table ~~(''Instruction: Can include references in the table'')~~		Put your text here and fill in the table

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 94:		Line 93:
	==Individual Region Genomic Gain/Loss/LOH==		==Individual Region Genomic Gain/Loss/LOH==

	Put your text here and fill in the table ~~(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'')~~		Put your text here and fill in the table

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 140:		Line 139:
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==

	Put your text here ''(EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)''		Put your text here

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 162:		Line 161:
	==Gene Mutations (SNV/INDEL)==		==Gene Mutations (SNV/INDEL)==

	Put your text here and fill in the table (''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)''		Put your text here and fill in the table

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 199:		Line 198:
	==Genes and Main Pathways Involved==		==Genes and Main Pathways Involved==

	Put your text here and fill in the table ~~''(Instructions: Can include references in the table.)''~~		Put your text here and fill in the table
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
Line 222:		Line 221:
	==Familial Forms==		==Familial Forms==

	Put your text here ~~(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'')~~		Put your text here

	==Additional Information==		==Additional Information==
Line 230:		Line 229:
	==Links==		==Links==

	Put your text placeholder here (use "Link" icon at top of page~~) (''Instructions: For example, link to related gene pages within the site. Note: links will be converted using the link icon at top of page in the CCGA site.''~~)		Put your text placeholder here (use "Link" icon at top of page)

	==References==		==References==
	(use "Cite" icon at top of page)		(use "Cite" icon at top of page)

	~~(''Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated'')~~

	~~(''Instruction: If a PMID is not available, such as for a book, please include the entire reference in this section'')<references />~~
	===EXAMPLE Book===		===EXAMPLE Book===

Kilannin.Krysiak: Additional corrections after review

2021-10-29T15:40:14Z

Additional corrections after review

← Older revision		Revision as of 10:40, 29 October 2021
Line 72:		Line 72:
	==Chromosomal Rearrangements (Gene Fusions)==		==Chromosomal Rearrangements (Gene Fusions)==

	Put your text here and~~/or~~ fill in the table		Put your text here and fill in the table

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 120:		Line 120:

	Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).		Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference). Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
			\|-
			\|EXAMPLE

			8
			\|EXAMPLE Gain
			\|EXAMPLE

			chr8:1-145,138,636 [hg38]
			\|EXAMPLE

			chr8
			\|No
			\|No
			\|No
			\|EXAMPLE

			Common recurrent secondary finding for t(8;21) (add reference).
	\|}		\|}
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 149:		Line 166:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!'''Presumed Mechanism (Tumor Suppressor Gene (TSG) / Oncogene / Other)'''!!'''Prevalence (COSMIC/ TCGA/Other)'''!!'''Concomitant Mutations'''!!'''Mutually Exclusive Mutations'''		!Gene; Genetic Alteration!!'''Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)'''!!'''Prevalence (COSMIC / TCGA / Other)'''!!'''Concomitant Mutations'''!!'''Mutually Exclusive Mutations'''
	!'''Diagnostic Significance (Yes, No or Unknown)'''		!'''Diagnostic Significance (Yes, No or Unknown)'''
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
Line 188:		Line 205:
	\|-		\|-
	\|EXAMPLE: BRAF and MAP2K1; Activating mutations		\|EXAMPLE: BRAF and MAP2K1; Activating mutations

	~~EXAMPLE: CDKN2A; Inactivating mutations~~

	~~EXAMPLE: KMT2C and ARID1A; Inactivating mutations~~
	\|EXAMPLE: MAPK signaling		\|EXAMPLE: MAPK signaling

	~~EXAMPLE: Cell cycle regulation~~

	~~EXAMPLE: Histone modification, chromatin remodeling~~
	\|EXAMPLE: Increased cell growth and proliferation		\|EXAMPLE: Increased cell growth and proliferation
			\|-
	EXAMPLE: Unregulated cell division		\|EXAMPLE: CDKN2A; Inactivating mutations
			\|EXAMPLE: Cell cycle regulation
	EXAMPLE: Abnormal gene expression program		\|EXAMPLE: Unregulated cell division
			\|-
			\|EXAMPLE: KMT2C and ARID1A; Inactivating mutations
			\|EXAMPLE: Histone modification, chromatin remodeling
			\|EXAMPLE: Abnormal gene expression program
	\|}		\|}
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

Kilannin.Krysiak: Added new tables to disease specific page

2021-10-29T15:33:02Z

Added new tables to disease specific page

@@ Line 77: / Line 77: @@
 |-
 !Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
-|'''Diagnostic Significance''' (Yes, No or Unknown)
+!Diagnostic Significance (Yes, No or Unknown)
-|'''Prognostic Significance''' (Yes, No or Unknown)
+!Prognostic Significance (Yes, No or Unknown)
-|'''Therapeutic Significance''' (Yes, No or Unknown)
+!Therapeutic Significance (Yes, No or Unknown)
-|'''Notes'''
+!Notes
 |-
 |EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
@@ Line 96: / Line 96: @@
 Put your text here and fill in the table (''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'')
 ==Characteristic Chromosomal Patterns==
 Put your text here ''(EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)''
 ==Gene Mutations (SNV/INDEL)==
@@ Line 139: / Line 182: @@
 ==Genes and Main Pathways Involved==
 Put your text here and fill in the table ''(Instructions: Can include references in the table.)''
 ==Genetic Diagnostic Testing Methods==
@@ Line 161: / Line 223: @@
 (''Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated'')
 (''Instruction: If a PMID is not available, such as for a book, please include the entire reference in this section'')<references />

Kilannin.Krysiak: Updating text for template

2021-10-29T15:24:34Z

Updating text for template

← Older revision		Revision as of 10:24, 29 October 2021
Line 77:		Line 77:
	\|-		\|-
	!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence		!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
	\|'''Diagnostic Significance (Yes, No or Unknown)~~Signs and Symptoms'''~~		\|'''Diagnostic Significance''' (Yes, No or Unknown)
	\|'''Prognostic Significance (Yes, No or Unknown)~~Signs and Symptoms'''~~		\|'''Prognostic Significance''' (Yes, No or Unknown)
	\|'''Therapeutic Significance (Yes, No or Unknown)~~Signs and Symptoms'''~~		\|'''Therapeutic Significance''' (Yes, No or Unknown)
	\|'''~~NotesSigns and Symptoms~~'''		\|'''Notes'''
	\|-		\|-
	\|EXAMPLE t(9;22)(q34;q11.2)\|\|EXAMPLE 3'ABL1 / 5'BCR\|\|EXAMPLE der(22)\|\|EXAMPLE 20% (COSMIC)		\|EXAMPLE t(9;22)(q34;q11.2)\|\|EXAMPLE 3'ABL1 / 5'BCR\|\|EXAMPLE der(22)\|\|EXAMPLE 20% (COSMIC)
Line 94:		Line 94:
	==Individual Region Genomic Gain/Loss/LOH==		==Individual Region Genomic Gain/Loss/LOH==

	Put your text here		Put your text here and fill in the table (''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'')

	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==

	Put your text here		Put your text here ''(EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)''

	==Gene Mutations (SNV/INDEL)==		==Gene Mutations (SNV/INDEL)==

	Put your text here and/or ~~fill~~ in the tables		Put your text here and fill in the table (''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)''

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~Mutation!!Oncogene/~~Tumor Suppressor~~/Other!!Presumed Mechanism~~ (~~LOF~~/~~GOF~~/Other~~; Driver/Passenger~~)!!Prevalence (COSMIC/TCGA/Other)		!Gene; Genetic Alteration!!'''Presumed Mechanism (Tumor Suppressor Gene (TSG) / Oncogene / Other)'''!!'''Prevalence (COSMIC/ TCGA/Other)'''!!'''Concomitant Mutations'''!!'''Mutually Exclusive Mutations'''
			!'''Diagnostic Significance (Yes, No or Unknown)'''
			!Prognostic Significance (Yes, No or Unknown)
			!Therapeutic Significance (Yes, No or Unknown)
			!Notes
	\|-		\|-
	\|EXAMPLE TP53\|\|EXAMPLE ~~R273H~~\|\|EXAMPLE ~~Tumor Suppressor~~\|\|~~EXAMPLE LOF~~\|\|EXAMPLE ~~20%~~		\|EXAMPLE: TP53; Variable LOF mutations
	\|}
			EXAMPLE:

			EGFR; Exon 20 mutations

			EXAMPLE: BRAF; Activating mutations
			\|EXAMPLE: TSG
			\|EXAMPLE: 20% (COSMIC)

			EXAMPLE: 30% (add Reference)
			\|EXAMPLE: IDH1 R123H
			\|EXAMPLE: EGFR amplification
			\|
			\|
			\|
			\|EXAMPLE: Excludes hairy cell leukemia (HCL) (add reference).
			<br />
			\|}
			Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

	==Epigenomic Alterations==		==Epigenomic Alterations==

Line 117:		Line 139:
	==Genes and Main Pathways Involved==		==Genes and Main Pathways Involved==

	Put your text here		Put your text here and fill in the table ''(Instructions: Can include references in the table.)''

	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==
Line 125:		Line 147:
	==Familial Forms==		==Familial Forms==

	Put your text here		Put your text here (''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'')

	==Additional Information==		==Additional Information==
Line 133:		Line 155:
	==Links==		==Links==

	Put your ~~links~~ here (use "Link" icon at top of page)		Put your text placeholder here (use "Link" icon at top of page) (''Instructions: For example, link to related gene pages within the site. Note: links will be converted using the link icon at top of page in the CCGA site.'')

	==References==		==References==
	(use "Cite" icon at top of page)		(use "Cite" icon at top of page)
	<references />
			(''Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated'')


			(''Instruction: If a PMID is not available, such as for a book, please include the entire reference in this section'')<references />
	===EXAMPLE Book===		===EXAMPLE Book===

Line 143:		Line 169:

	==Notes==		==Notes==
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

Kilannin.Krysiak: Altering major sections of this template

2021-10-25T17:43:32Z

Altering major sections of this template

← Older revision		Revision as of 12:43, 25 October 2021
Line 92:		Line 92:
	\|}		\|}

	==~~Characteristic Chromosomal Aberrations~~ / ~~Patterns~~==		==Individual Region Genomic Gain/Loss/LOH==

	Put your text here		Put your text here

	==~~Genomic Gain/Loss/LOH~~==		==Characteristic Chromosomal Patterns==

	Put your text here ~~and/or fill in the table~~		Put your text here

	~~{\| class="wikitable sortable"~~
	\|-
	~~!Chromosome Number!!Gain/Loss/Amp/LOH!!Region~~
	\|-
	~~\|EXAMPLE 8\|\|EXAMPLE Gain\|\|EXAMPLE chr8:0-1000000~~
	\|-
	~~\|EXAMPLE 7\|\|EXAMPLE Loss\|\|EXAMPLE chr7:0-1000000~~
	\|}

	==Gene Mutations (SNV/INDEL)==		==Gene Mutations (SNV/INDEL)==

Line 119:		Line 110:
	\|EXAMPLE TP53\|\|EXAMPLE R273H\|\|EXAMPLE Tumor Suppressor\|\|EXAMPLE LOF\|\|EXAMPLE 20%		\|EXAMPLE TP53\|\|EXAMPLE R273H\|\|EXAMPLE Tumor Suppressor\|\|EXAMPLE LOF\|\|EXAMPLE 20%
	\|}		\|}

	==~~=Other Mutations===~~		==Epigenomic Alterations==
	~~{\| class="wikitable sortable"~~
	\|-
	~~!Type!!Gene/Region/Other~~
	\|-
	~~\|Concomitant Mutations\|\|EXAMPLE IDH1 R123H~~
	\|-
	~~\|Secondary Mutations\|\|EXAMPLE Trisomy 7~~
	\|-
	~~\|Mutually Exclusive\|\|EXAMPLE EGFR Amplification~~
	\|}

	~~==Epigenomics (Methylation)~~==

	Put your text here		Put your text here
Line 140:		Line 119:
	Put your text here		Put your text here

	==Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

	Put your text here		Put your text here

	~~==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)==~~

	~~Diagnosis: Put your text here~~

	~~Prognosis: Put your text here~~

	~~Therapeutic: Put your text here~~

	==Familial Forms==		==Familial Forms==
Line 156:		Line 127:
	Put your text here		Put your text here

	==~~Other~~ Information==		==Additional Information==

	Put your text here		Put your text here

Kilannin.Krysiak: Updated first half of the template. Additional changes are pending.

2021-10-25T17:40:05Z

Updated first half of the template. Additional changes are pending.

← Older revision		Revision as of 12:40, 25 October 2021
Line 1:		Line 1:
	~~{{Under Construction}}~~		''(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions]] and [[Frequently Asked Questions (FAQs)\|FAQs]] as well as contact your [[Leadership\|Associate Editor]] or [[Mailto:CCGA@cancergenomics.org\|Technical Support]].)''
	==Primary Author(s)*==		==Primary Author(s)*==

	Put your text here (~~Example~~: Jane Smith, PhD, Institute of Genomics)		Put your text here (''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics)

	__TOC__		__TOC__
Line 16:		Line 16:
	==Definition / Description of Disease==		==Definition / Description of Disease==

	Put your text here		Put your text here (''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'')

	==Synonyms / Terminology==		==Synonyms / Terminology==

	Put your text here		Put your text here (''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'')

	==Epidemiology / Prevalence==		==Epidemiology / Prevalence==
Line 28:		Line 28:
	==Clinical Features==		==Clinical Features==

	Put your text here		Put your text here and fill in the table (''Instruction: Can include references in the table'')
			{\| class="wikitable"
			\|'''Signs and Symptoms'''
			\|EXAMPLE Asymptomatic (incidental finding on complete blood counts)

			EXAMPLE B-symptoms (weight loss, fever, night sweats)

			EXAMPLE Fatigue

			EXAMPLE Lymphadenopathy (uncommon)
			\|-
			\|'''Laboratory Findings'''
			\|EXAMPLE Cytopenias

			EXAMPLE Lymphocytosis (low level)
			\|}

	==Sites of Involvement==		==Sites of Involvement==

	Put your text here		Put your text here (''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'')

	==Morphologic Features==		==Morphologic Features==
Line 40:		Line 55:
	==Immunophenotype==		==Immunophenotype==

	Put your text here and~~/or~~ fill in the table		Put your text here and fill in the table (''Instruction: Can include references in the table'')

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 62:		Line 77:
	\|-		\|-
	!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence		!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
			\|'''Diagnostic Significance (Yes, No or Unknown)Signs and Symptoms'''
			\|'''Prognostic Significance (Yes, No or Unknown)Signs and Symptoms'''
			\|'''Therapeutic Significance (Yes, No or Unknown)Signs and Symptoms'''
			\|'''NotesSigns and Symptoms'''
	\|-		\|-
	\|EXAMPLE t(9;22)(q34;q11.2)\|\|EXAMPLE 3'ABL1 / 5'BCR\|\|EXAMPLE der(22)\|\|EXAMPLE 5%		\|EXAMPLE t(9;22)(q34;q11.2)\|\|EXAMPLE 3'ABL1 / 5'BCR\|\|EXAMPLE der(22)\|\|EXAMPLE 20% (COSMIC)
	\|-		EXAMPLE 30% (add reference)
	\|EXAMPLE t(8;21)(~~q22;q22~~)~~\|\|EXAMPLE 5'RUNX1 / 3'RUNXT1\|\|EXAMPLE der~~(8)~~\|\|EXAMPLE 5%~~		\|Yes
			\|No
			\|Yes
			\|EXAMPLE

			The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
	\|}		\|}

Jennelleh at 16:06, 20 October 2021

2021-10-20T16:06:22Z

Show changes

Jennelleh: Created page with "??"

2021-10-20T16:06:04Z

Created page with "??"

New page